GlassScriptPhysician profile
James B Mcgeady
NPI 1194921486
$6,394.57
in general payments reported to CMS, 2019-2025
48 companies · $793 in 2025
The $793 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $946 · 2020: $698 · 2021: $690 · 2022: $804 · 2023: $1,155 · 2024: $1,307 · 2025: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,255.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $995.39 | 2019-2025 | Erleada |
| Astellas Pharma US INC | $630.64 | 2019-2022 | |
| Boston Scientific Corporation | $577.77 | 2019-2025 | Ams 700, Lumenis Pulse 120h, Ams 800 Artificial Urinary Sphincter |
| Pfizer INC. | $426.92 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $295.63 | 2019-2025 | |
| Coloplast Corp | $274.09 | 2020-2024 | Speedicath |
| Dendreon Pharmaceuticals LLC | $263.15 | 2019-2025 | Provenge |
| Merck Sharp & Dohme LLC | $261.38 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Endo Pharmaceuticals INC. | $260.61 | 2019-2024 | Xiaflex, Aveed |
| Sumitomo Pharma America, INC. | $204.10 | 2023-2025 | Gemtesa, Orgovyx |
| Urogen Pharma, INC. | $142.83 | 2021-2025 | Jelmyto |
| Astrazeneca Pharmaceuticals LP | $142.67 | 2020-2025 | Lynparza |
| Accord Healthcare, INC. | $137.02 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $121.53 | 2019-2024 | Adstiladrin |
| Allergan, INC. | $116.71 | 2019-2021 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mcgeady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.